Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Conmed (CNMD) Shares Issued (2019)

Conmed filings provide 7 years of Shares Issued readings, the most recent being $30.6 million for Q1 2019.

On a quarterly basis, Shares Issued changed N/A to $30.6 million in Q1 2019 year-over-year; TTM through Dec 2019 was $30.6 million, a N/A change, with the full-year FY2022 number at $72.0 million, changed N/A from a year prior.
Shares Issued hit $30.6 million in Q1 2019 for Conmed, up from $169000.0 in the prior quarter.
In the past five years, Shares Issued ranged from a high of $30.6 million in Q1 2019 to a low of $169000.0 in Q4 2015.